Karyopharm Therapeutics (KPTI) Misses Q2 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Karyopharm (KPTI) Sell-Off Overdone, Leerink Partners Says
August 11, 2015 7:58 AM EDTLeerink Partners analyst Michael Schmidt reiterated an Outperform rating but lowered his price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $41.00 (from $58.00) following yesterday's sell-off. The analyst said the move is overdone in their view.
Schmidt commented, "KPTI reported 2Q15 financial results and provided a pipeline update. Mgmt announced it... More
Karyopharm Therapeutics (KPTI) Moves to Session Lows
August 10, 2015 2:00 PM EDTKaryopharm Therapeutics (NASDAQ: KPTI) has moved to session lows following Q2 results reported before markets opened Monday. Shares are down over 39 percent and reached a 52-week low at $13.36 today. Volume at over 1.7 million shares compares with average daily volume of about 335,000 shares.
KPTI... More
